www.HemophiliaTreatmentReport.com
https://clinicaltrials.gov/ct2/show/NCT03974113?type=Intr&cond=hemophilia&lupd_s=05%2F21%2F2019&lupd_d=14
Condition : Hemophilia
Intervention : Drug: Fitusiran
Sponsor : Genzyme, a Sanofi Company
Not yet recruiting
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
NCT03974113
Tue, 04 Jun 2019 12:00:00 EDT
Last Update Posted: 06/04/19 06:53AM
https://clinicaltrials.gov/ct2/show/NCT03196297?type=Intr&cond=hemophilia&lupd_s=05%2F08%2F2019&lupd_d=14
Conditions : Haemostasis; Haemophilia A
Interventions : Drug: Concizumab; Drug: Turoctocog alfa
Sponsor : Novo Nordisk A/S
Active, not recruiting
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
NCT03196297
Thu, 22 Jun 2017 12:00:00 EDT
Last Update Posted: 05/22/19 07:39AM
https://clinicaltrials.gov/ct2/show/NCT03196284?type=Intr&cond=hemophilia&lupd_s=05%2F08%2F2019&lupd_d=14
Conditions : Congenital Bleeding Disorder; Haemophilia A With Inhibitors; Haemophilia B With Inhibitors
Interventions : Drug: Concizumab; Drug: Eptacog alfa
Sponsor : Novo Nordisk A/S
Active, not recruiting
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
NCT03196284
Thu, 22 Jun 2017 12:00:00 EDT
Last Update Posted: 05/22/19 07:39AM
https://clinicaltrials.gov/ct2/show/NCT03307980?type=Intr&cond=hemophilia&lupd_s=04%2F10%2F2019&lupd_d=14
Condition : Hemophilia B
Intervention : Biological: SPK-9001
Sponsor : Pfizer
Recruiting
Long-term Safety and Efficacy Study of SPK-9001 in Individuals With Hemophilia B
NCT03307980
Thu, 12 Oct 2017 12:00:00 EDT
Last Update Posted: 04/24/19 07:45AM
https://clinicaltrials.gov/ct2/show/NCT03520712?type=Intr&cond=hemophilia&lupd_s=03%2F25%2F2019&lupd_d=14
Conditions : Haemophilia A; Gene Therapy; Clotting Disorders; Blood Disorder
Intervention : Biological: Valoctocogene Roxaparvovec
Sponsor : BioMarin Pharmaceutical
Enrolling by invitation
Gene Therapy Study in Severe Haemophilia A Patients With Antibodies Against AAV5
NCT03520712
Thu, 10 May 2018 12:00:00 EDT
Last Update Posted: 04/08/19 08:25AM
https://clinicaltrials.gov/ct2/show/NCT02396342?type=Intr&cond=hemophilia&lupd_s=03%2F12%2F2019&lupd_d=14
Condition : Hemophilia B
Intervention : Genetic: AAV5-hFIX
Sponsor : UniQure Biopharma B.V.
Active, not recruiting
Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B
NCT02396342
Tue, 24 Mar 2015 12:00:00 EDT
Last Update Posted: 03/26/19 09:35AM
https://clinicaltrials.gov/ct2/show/NCT02484092?type=Intr&cond=hemophilia&lupd_s=03%2F08%2F2019&lupd_d=14
Condition : Hemophilia B
Intervention : Biological: SPK-9001
Sponsor : Pfizer
Active, not recruiting
A Gene Therapy Study for Hemophilia B
NCT02484092
Mon, 29 Jun 2015 12:00:00 EDT
A Phase 1/2, Open-Label, Non-Randomized, Dose-Escalation Study of SPK-9001 in Subjects with Hemophilia B
Last Update Posted: 03/22/19 09:19AM
https://clinicaltrials.gov/ct2/show/NCT01580293?type=Intr&cond=hemophilia&lupd_s=03%2F01%2F2019&lupd_d=14
Condition : Hemophilia A
Intervention : Biological: BAY94-9027
Sponsor : Bayer
Active, not recruiting
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A
NCT01580293
Thu, 19 Apr 2012 12:00:00 EDT
Last Update Posted: 03/15/19 11:40AM
https://clinicaltrials.gov/ct2/show/NCT03003533?type=Intr&cond=hemophilia&lupd_s=02%2F27%2F2019&lupd_d=14
Condition : Hemophilia A
Intervention : Genetic: SPK-8011
Sponsor : Spark Therapeutics
Recruiting
A Gene Transfer Study for Hemophilia A
NCT03003533
Wed, 28 Dec 2016 12:00:00 EST
Last Update Posted: 03/13/19 10:19AM
https://clinicaltrials.gov/ct2/show/NCT03734588?type=Intr&cond=hemophilia&lupd_s=02%2F27%2F2019&lupd_d=14
Conditions : Adeno-Associated Virus (AAV); Blood Coagulation Disorder; Blood Coagulation Disorders, Inherited; Coagulation Protein Disorders; Factor VIII (FVIII); Factor VIII (FVIII) Deficiency; Factor VIII (FVIII) Gene; Factor VIII (FVIII) Protein; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Gene Therapy; Gene Transfer; Hematologic Diseases; Hemorrhagic Disorders; Recombinant; Vector; Inhibitors
Intervention : Genetic: SPK-8016
Sponsor : Spark Therapeutics
Recruiting
Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors
NCT03734588
Thu, 08 Nov 2018 12:00:00 EST
Last Update Posted: 03/13/19 10:19AM
https://clinicaltrials.gov/ct2/show/NCT03597022?type=Intr&cond=hemophilia&lupd_s=02%2F26%2F2019&lupd_d=14
Condition : Hemophilia A and B
Intervention : Drug: BAY1093884
Sponsor : Bayer
Recruiting
Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors
NCT03597022
Tue, 24 Jul 2018 12:00:00 EDT
Last Update Posted: 03/12/19 09:58AM
https://clinicaltrials.gov/ct2/show/NCT03061201
https://clinicaltrials.gov/ct2/show/NCT03588299?type=Intr&cond=hemophilia&lupd_s=02%2F20%2F2019&lupd_d=14
Condition : Hemophilia A
Intervention : Drug: BAY2599023 (DTX201)
Sponsors : Bayer; Ultragenyx Pharmaceutical Inc
Recruiting
Factor VIII Gene Therapy Study in Patients With Hemophilia A
NCT03588299
Tue, 17 Jul 2018 12:00:00 EDT
Last Update Posted: 03/06/19 06:39PM
https://clinicaltrials.gov/ct2/show/NCT03363321
https://clinicaltrials.gov/ct2/show/NCT02196207
